Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of GPC2-CAR T Cells for Relapsed/Refractory Medulloblastoma
NCT07087002Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- Aug 2025
- Primary completion
- Aug 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in medulloblastoma, central nervous system embryonal tumor, embryonal tumor with multilayered rosettes (ETMR) and 3 more, sponsored by Stanford University. Primary endpoints: Manufacturing Feasibility at 6 months and Incidence of Dose Limiting Toxicities at 28 days. Started Aug 2025; status: recruiting.
02
Conditions
medulloblastomacentral nervous system embryonal tumorembryonal tumor with multilayered rosettes (ETMR)pineoblastoma (PB)Atypical teratoid rhabdoid tumor (ATRT)
Beyond the preview
Go deeper on NCT07087002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07087002.